中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 10
Oct.  2018
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2018  >  34(10): 2241-2244

Application of anticoagulants after transjugular intrahepatic portosystemic shunt

DOI: 10.3969/j.issn.1001-5256.2018.10.040

  • Department of Gastroenterology, The Second Affiliated Hospital of Kunming Medical University

Research funding:

 

  • Received Date: 2018-04-28
  • Published Date: 2018-10-20
    Abstract
  • Transjugular intrahepatic portosystemic shunt ( TIPS) , after nearly 30 years of continuous exploration and development, has been widely used in the treatment of complications of portal hypertension. TIPS has significant advantages in acute esophagogastric variceal bleeding, prevention of rebleeding, refractory peritoneal effusion, and Budd-Chiari syndrome; however, if postoperative anticoagulant measures are inappropriate, it can cause several complications, such as stent dysfunction and acute thrombosis, and lead to the recurrence of the symptoms of portal hypertension before TIPS, which greatly affects middle-and long-term clinical outcomes and survival rate. Maintenance of stent patency is the key to good postoperative treatment outcome, and therefore, anticoagulants play an important role in the prevention and treatment of post-TIPS thrombosis. At present, no consensus has been reached on post-TIPS anticoagulant therapy in China and foreign countries. This article reviews the research advances in the application of anticoagulants after TIPS.

     

    • FullText(HTML)
  • loading
    • References(41)
  • [1]ZHANG Y, ZHANG H, ELIZABETH A, et al.Epidemiology o hepatitis B and associated liver diseases in China[J].Chin Med Sci J, 2012, 27 (4) :243-248.
    [2]BOSCH J, ABRALDES J, GROSZMANN R.Current management o portal hypertension[J].J Hepatol, 2003, 38 (1) :54-68.
    [3]QI XS, BAI M, YANG ZP, et al.Selection of a TIPS stent for management of portal hypertension in liver cirrhosis:An evidencebased review[J].World J Gastroenterol, 2014, 20 (21) :6470-6480.
    [4]ORLOFF MJ, HYE RJ, WHEELER HO, et al.Randomized trials of endoscopic therapy and transjugular intrahepatic portosystemic shunt versus portacaval shunt for emergency and elective treatment of bleeding gastric varices in cirrhosis[J].Surgery, 2015, 157 (6) :1028-1045.
    [5]GARCA-PAGN JC, CACA K, BUREAU C, et al.Early use of TIPS in patients with cirrhosis and variceal bleeding[J].Ann Intern Med, 2010, 153 (10) :5-13.
    [6]SUHOCKI PV, LUNGREN MP, KAPOOR B, et al.Transjugular intrahepatic portosystemic shunt complications:prevention and management[J].Semin Intervent Radiol, 2015, 32 (2) :123.
    [7]WAN YM, LI YH, WU HM, et al.Portal vein thrombosis before and after transjugular intrahepatic portosystemic shunt placement:An observational study (STROBE compliant) [J].Medicine, 2017, 96 (45) :e8498.
    [8]GAZZERA C, RIGHI D, DORIGUZZI BA, et al.Emergency transjugular intrahepatic portosystemic shunt (TIPS) :results, complications and predictors of mortality in the first month of follow-up[J].Radiol Med, 2012, 117 (1) :46-53.
    [9]BAI M, HE CY, QI XS, et al.Shunting branch of portal vein and stent position predict survival after transjugular intrahepatic portosystemic shunt[J].World J Gastroenterol, 2014, 20 (3) :774-785.
    [10]BUREAU C, GARCIA-PAGAN JC, OTAL P, et al.Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS:Results of a randomized study[J].Gastroenterology, 2004, 126 (2) :469-475.
    [11]PAN JJ, CHEN C, GELLER B, et al.Is sonographic surveillance of polytetrafluoroethylene-covered transjugular intrahepatic portosystemic shunts (TIPS) necessary?A single centre experience comparing both types of stents[J].Clin Radiol, 2008, 63 (10) :1142-1148.
    [12]MENZEL J, VESTRING T, FOERSTER EC, et al.Arterio-biliary fistula after transjugular intrahepatic portosystemic shunt:A lifethreatening complication of the new technique for therapy of portal hypertension[J].Z Gastroenterol, 1995, 33 (5) :255-259.
    [13]CURA M, CURA A, SURI R, et al.Causes of TIPS dysfunction[J].Ajr Am J Roentgenol, 2008, 191 (6) :1751-1757.
    [14]BAGLIN T, BARROWCLIFFE TW, COHEN A, et al.Guidelines on the use and monitoring of heparin[J].Br J Haematol, 2006, 133 (1) :19-34.
    [15]UCHIDA Y, MORI F, OGAWA H, et al.Impact of anticoagulant therapy with dual antiplatelet therapy on prognosis after treatment with drug-eluting coronary stents[J].J Cardiol, 2010, 55 (3) :362-369.
    [16]RSSLE M, GERBES AL.TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax:A critical update[J].Gut, 2010, 59 (7) :988-990.
    [17]COLOMBATO L.The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension[J].Hepatology, 2010, 51 (1) :386-400.
    [18]DE FR, FACULTY BV.Expanding consensus in portal hypertension:Report of the Baveno VI Consensus Workshop:Stratifying risk and individualizing care for portal hypertension[J].J Hepatol, 2015, 63 (3) :743-752.
    [19]OFLIVER EAF.EASL clinical practice guidelines:Vascular diseases of the liver[J].J Hepatol, 2016, 64 (1) :179-202.
    [20]VEITCH AM, VANBIERVLIET G, GERSHILICH AH, et al.Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants:British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines[J].Endoscopy, 2016, 48 (04) :385-402.
    [21]Interventional Group, Chinese Society of Radiology, Chinese Medical Association.Expert consensus on transjugular intrahepatic portosystemic shunt[J].J Clin Hepatol, 2017, 33 (7) :1218-1228. (in Chinese) 中华医学会放射学分会介入学组.经颈静脉肝内门体分流术专家共识[J].临床肝胆病杂志, 2017, 33 (7) :1218-1228.
    [22]SENZOLO M, RODRIGUEZ-CASTRO KI, ROSSETTO V, et al.Increased anticoagulant response to low-molecular-weight heparin in plasma from patients with advanced cirrhosis[J].J Thromb Haemost, 2012, 10 (9) :1823-1829.
    [23]BECHMANN LP, SICHAU M, WICHERT M, et al.Low-molecular-weight heparin in patients with advanced cirrhosis[J].Liver Int, 2015, 31 (1) :75-82.
    [24]RSSLE M, BAUSCH B, KLINGER C.Therapy algorithm for portal vein thrombosis in liver cirrhosis:The internist's point of view[J].Viszeralmedizin, 2014, 30 (6) :401-408.
    [25]WAN YM, LI YH, WU HM, et al.Portal vein thrombosis in patients with cirrhosis undergoing elective transjugular intrahepatic portosystemic shunt[J].Clin Appl Thromb Hemost, 2018, 24 (3) :462-470.
    [26]LI LX, YI SP, LIANG FF, et al.Analysis of the influence factors of portal vein thrombosis after TIPS[J].Mod Digest Interv, 2017, 22 (6) :772-776. (in Chinese) 黎丽旋, 易颂平, 梁芬芬, 等.TIPS术后门静脉血栓形成的影响因素分析[J].现代消化及介入诊疗, 2017, 22 (6) :772-776.
    [27]WANG Z, JIANG MS, ZHAGN HL, et al.Is Post-TIPS anticoagulation therapy necessary in patients with cirrhosis and portal vein thrombosis?A randomized controlled trial[J].Radiology, 2016, 279 (3) :943-951.
    [28]INTAGLIATA NM, HENRY ZH, SHAH N, et al.Prophylactic anticoagulation for venous thromboembolism in hospitalized cirrhosis patients is not associated with high rates of gastrointestinal bleeding[J].Liver Int, 2014, 34 (1) :26-32.
    [29]JAMES K, BERTOJA E, O'BEIRNE J, et al.Use of thromboelastography Platelet Mapping to monitor antithrombotic therapy in a patient with Budd-Chiari syndrome[J].Liver Transpl, 2010, 16 (1) :38-41.
    [30]DING Y, WANG LZ, SONG J, et al.The influence of CYP2C19 gene polymorphism on the curative effect of clopidogrel in patients after receiving TIPS[J].J Intervent Radiol, 2017, 26 (7) :588-593. (in Chinese) 丁远, 王黎洲, 宋杰, 等.细胞色素P450酶2C19基因多态性对TIPS术后患者服用氯吡格雷效果的影响[J].介入放射学杂志, 2017, 26 (7) :588-593.
    [31]TUMMALA R, KAVTARADZE A, GUPTA A, et al.Specific antidotes against direct oral anticoagulants:A comprehensive review of clinical trials data[J].Int J Cardiol, 2016, 214:292-298.
    [32]LAUX V, PERZBORN E, KUBITA D, et al.Preclinical and clinical characteristics of rivaroxaban:a novel, oral, direct factor Xa inhibitor[J].Semin Thromb Hemost, 2007, 33 (5) :515-523.
    [33]YANG R, XU HS, ZHANG ZL, et al.Effect of drug interaction on anticoagulant strength of warfarin[J].Chin J Clin Pharmacol Ther, 2017, 22 (12) :1426-1431. (in Chinese) 杨瑞, 许海沙, 张赞玲, 等.药物相互作用对华法林抗凝强度的影响分析[J].中国临床药理学与治疗学, 2017, 22 (12) :1426-1431.
    [34]VILASECA M, GARCA-CALDERH, LAFOZ E, et al.The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells[J].Hepatology, 2017, 65 (6) :2031.
    [35]LISMAN T, KAMPHUISEN PW, NORTHUP PG, et al.Established and new-generation antithrombotic drugs in patients with cirrhosis-Possibilities and caveats[J].J Hepatol, 2013, 59 (2) :358-366.
    [36]LI XY, LU Y, LIU YX, et al.Compare anticoagulation effects of rivaroxaban with low molecular weight heparin in patients after transjugular intrahepatic portasystemic stent shunt[J].Chin J New Drugs Clin Remed, 2016, 35 (6) :419-422. (in Chinese) 黎小妍, 陆英, 刘玉兴, 等.利伐沙班与低分子肝素对经颈静脉肝内门体分流术后患者的抗凝疗效比较[J].中国新药与临床杂志, 2016, 35 (6) :419-422.
    [37]GRAFF J, HARDER S.Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment[J].Clin Pharmacokinet, 2013, 52 (4) :243-254.
    [38]STANGIER J, STAHLE H, RATHGEN K, et al.Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment[J].J Clin Pharmacol, 2008, 48 (12) :1411-1419.
    [39]STANGIER DJ, RATHGEN K, STAHLE H, et al.Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate[J].Clin Pharmacokinet, 2010, 49 (4) :259-268.
    [40]BLOMMEL ML, BLOMMEL AL.Dabigatran etexilate:A novel oral direct thrombin inhibitor[J].Am J Health Syst Pharm, 2011, 68 (16) :1506-1519.
    [41]TAKEUCHI H.A network of pulmonary vein thrombi is a risk factor for ischemic stroke, especially after cardiac surgery:A case report and mini review[J].Int J Cardiol Heart Vasc, 2015, 6:1-3.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1973) PDF downloads(380) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return